Cat. No. |
Product Name |
Information |
PC-73261 |
BMS-570520
CCR3 antagonist
|
BMS-570520 is a potent, selective CCR3 antagonist with IC50 of 1.9 nM, inhibits eotaxin-induced chemotaxis with IC50 of 0.068 nM. |
PC-73260 |
DPC168
CCR3 antagonist
|
DPC168 (DPC-168) is a highly potent, selective CC chemokine receptor-3 (CCR3) antagonist with IC50 of 2.0 nM, inhibits eotaxin-induced chemotaxis with IC50 of 0.034 nM. |
PC-73259 |
IS811
CCR3 antagonist
|
IS811 is a potent, selective CCR3 antagonist with IC50 of 2.0 nM, potently inhibits chemotaxis with EC50 of 19 nM. |
PC-73250 |
CCR7 inhibitor Cmp1205
CCR7 inhibitor
|
CCR7 inhibitor Cmp1205 is an allosteric ligand and antagonist for human CC chemokine receptor 7 (CCR7) with Kd of 3 nM, suppresses arrestin binding in response to activation by CCL19 with IC50 of 7.3 uM. |
PC-73249 |
Vercirnon
CCR9 inhibitor
|
Vercirnon (GSK1605786, CCX282-B) is a potent, selective, orally bioavailable antagonist of CCR9, inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 of 5.4 and 3.4 nM, respectively. |
PC-73125 |
SX-682
CXCR1/2 inhibitor
|
SX-682 (SX682) is a potent, allosteric, orally bioavailable inhibitor of CXCR1 and CXCR2. |
PC-73031 |
CCR4-351
CCR4 antagonist
|
CCR4-IN-38 (CCR4-351) is a potent, selective, orally bioavailable CCR4 antagonist with IC50 of 50 nM (Chemotaxis inhibition). |
PC-73030 |
CCR4-IN-31
CCR4 antagonist
|
CCR4-IN-31 is a potent, selective, orally bioavailable CCR4 antagonist with IC50 of 40 nM (Ca2+ flux). |
PC-72905 |
EMU-116
CXCR4 antagonist
|
EMU-116 (EMU-000116) is a potent, selective CXCR4 antagonist with IC50 29.6 nM in Ca2+ flux assay. |
PC-72896 |
CCR2 inhibitor SD-24
CCR2 inhibitor
|
CCR2 inhibitor SD-24 is a potent selective CCR2 antagonist with pKi of 8.5. |
PC-72895 |
CCR2 Covalent-IN-14
CCR2 inhibitor
|
CCR2 covalent-IN-14 is a covalent, negative allosteric modulator (NAM) of CCR2, binds to intracellularly pocket of CCR2 with Ki of 4 nM. |
PC-72668 |
BMS-813160
CCR2/5 inhibitor
|
BMS-813160 (BMS 813160) a potent and selective CCR2/5 dual antagonist with binding IC50 of 6.2/3.6 nM, respectively. |